FDA rejects Alkermes' depression drug, questions effectiveness
February 01, 2019 at 17:08 PM EST
The FDA has rejected Alkermes' depression drug, echoing past questions around the drug's effectiveness and the data the company presented. The company's stock price fell 4 percent in after-hours trading and has fallen 19 percent since last fall.